Microbot Medical to showcase FDA-cleared robotic system at conference

HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), a medical device company with a market capitalization of $205 million and showing strong momentum with a 20% gain last week, announced that CEO Harel Gadot will present the company’s recently FDA-cleared LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference today.

The presentation, scheduled for 9:00 a.m. ET, will highlight the LIBERTY System, which the company describes as the first single-use, remotely operated robotic system designed for peripheral endovascular procedures.

According to the press release statement, the system aims to enhance precision, efficiency and provider safety during endovascular procedures. The presentation will be accessible through the company’s website.

Microbot Medical, headquartered in Massachusetts, focuses on developing robotic technology for endovascular procedures. The company states that its LIBERTY system received FDA clearance, representing a significant regulatory milestone for the product.

The company’s stock is traded on the Nasdaq under the ticker symbol MBOT.

The information in this article is based on a press release issued by Microbot Medical.

In other recent news, Microbot Medical has received 510(k) clearance from the U.S. Food and Drug Administration for its LIBERTY Endovascular Robotic System. This clearance allows the company to begin commercialization in the U.S. market by the fourth quarter of 2025, targeting an initial market of approximately 2.5 million peripheral endovascular procedures annually. Additionally, Microbot Medical raised $5.9 million through the issuance of nearly 3 million shares from the exercise of various preferred investment options. In another development, H.C. Wainwright maintained its Buy rating for Microbot Medical, with a $9.00 price target, following a new patent grant for its LIBERTY robotic system. This patent covers a modular robotic surgical system with interchangeable tool-receiver units. Furthermore, Microbot Medical has appointed Christina Bailey, a former Olympian, as its new Vice President of Sales. Bailey brings 20 years of medical device sales experience and will report directly to CEO Harel Gadot. Gadot, who also serves as the founder and chairman of Microbot Medical, has been appointed as an independent director at Brenmiller Energy, expanding his leadership roles.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.